Mark Anthony McCamish insider trades

Open-market stock purchases and sales by Mark Anthony McCamish, Director at Avadel Pharmaceuticals plc, from SEC Form 4 filings since Dec 26, 2018.

Recent trades

DateStockTradeValue
Feb 12, 2026AVDL Avadel Pharmaceuticals plcSold (not open market)$462K
Feb 12, 2026AVDL Avadel Pharmaceuticals plcSold (not open market)$1.4M
Feb 12, 2026AVDL Avadel Pharmaceuticals plcSold (not open market)$355K
Feb 12, 2026AVDL Avadel Pharmaceuticals plcSold (not open market)$265K
Feb 12, 2026AVDL Avadel Pharmaceuticals plcSold (not open market)$119K
Feb 12, 2026AVDL Avadel Pharmaceuticals plcSold (not open market)$201K
Feb 12, 2026AVDL Avadel Pharmaceuticals plcSold (not open market)$465K
Feb 4, 2026AVDL Avadel Pharmaceuticals plcBought (not open market)—

Companies traded

  • AVDL Avadel Pharmaceuticals plc: 2 buys, 2 sales, last Feb 12, 2026
  • RFL Rafael Holdings, Inc: other filings, last Jan 5, 2024
  • VINC Vincera Pharma, Inc: other filings, last Dec 23, 2020
  • FTSV Forty Seven, Inc: 9 sales, last Apr 7, 2020

Get free alerts when Mark Anthony McCamish files a new trade →